Get the Stockscreener App
179.89
2.11%
3.71
Biogen Inc stock is traded at $179.89, with a volume of 1.49M.
It is up +2.11% in the last 24 hours and up +1.98% over the past month.
Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
See More
Previous Close:
$176.18
Open:
$177.09
24h Volume:
1.49M
Relative Volume:
0.76
Market Cap:
$26.39B
Revenue:
$9.61B
Net Income/Loss:
$1.53B
P/E Ratio:
17.21
EPS:
10.453
Net Cash Flow:
$1.85B
1W Performance:
+4.84%
1M Performance:
+1.98%
6M Performance:
+42.05%
1Y Performance:
+23.02%
1-Day Range:
$175.96
$180.14
1-Week Range:
$170.59
$180.14
52-Week Range:
$110.03
$190.20
Biogen Inc Stock (BIIB) Company Profile
Name
Biogen Inc
Sector
Industry
Phone
(781) 464-2000
Address
225 BINNEY STREET, CAMBRIDGE, MA
Compare BIIB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BIIB
Biogen Inc
|
179.89 | 25.85B | 9.61B | 1.53B | 1.85B | 10.45 |
|
LLY
Lilly Eli Co
|
1,037.15 | 916.62B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
227.25 | 547.61B | 94.19B | 26.80B | 20.46B | 11.05 |
|
ABBV
Abbvie Inc
|
223.01 | 389.58B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
148.68 | 285.73B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
110.27 | 268.90B | 63.90B | 19.05B | 13.05B | 7.5596 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-07-26 | Resumed | UBS | Neutral |
| Dec-10-25 | Downgrade | HSBC Securities | Hold → Reduce |
| Nov-06-25 | Upgrade | Stifel | Hold → Buy |
| Sep-25-25 | Initiated | Jefferies | Buy |
| Jul-21-25 | Resumed | Truist | Hold |
| Apr-28-25 | Downgrade | HSBC Securities | Buy → Hold |
| Apr-04-25 | Downgrade | Argus | Buy → Hold |
| Feb-11-25 | Initiated | Bernstein | Mkt Perform |
| Jan-02-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-20-24 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Dec-16-24 | Downgrade | Stifel | Buy → Hold |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Dec-09-24 | Downgrade | Jefferies | Buy → Hold |
| Nov-18-24 | Downgrade | Needham | Buy → Hold |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Oct-31-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Feb-14-24 | Reiterated | Needham | Buy |
| Feb-14-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-24-24 | Downgrade | UBS | Buy → Neutral |
| Dec-20-23 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-07-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Outperform |
| Jul-24-23 | Reiterated | UBS | Buy |
| May-01-23 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-17-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-26-22 | Upgrade | Goldman | Neutral → Buy |
| Oct-13-22 | Upgrade | Stifel | Hold → Buy |
| Oct-07-22 | Upgrade | Argus | Hold → Buy |
| Sep-28-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Sep-28-22 | Upgrade | Mizuho | Neutral → Buy |
| Sep-28-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Apr-18-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-08-22 | Downgrade | Stifel | Buy → Hold |
| Mar-03-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Feb-04-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Feb-04-22 | Reiterated | Barclays | Equal Weight |
| Feb-04-22 | Reiterated | BofA Securities | Neutral |
| Feb-04-22 | Reiterated | Cowen | Outperform |
| Feb-04-22 | Reiterated | Morgan Stanley | Overweight |
| Feb-04-22 | Reiterated | Needham | Buy |
| Feb-04-22 | Reiterated | Oppenheimer | Outperform |
| Feb-04-22 | Reiterated | RBC Capital Mkts | Sector Perform |
| Feb-04-22 | Reiterated | Robert W. Baird | Neutral |
| Feb-04-22 | Reiterated | Wedbush | Neutral |
| Feb-04-22 | Reiterated | Wells Fargo | Equal Weight |
| Feb-04-22 | Reiterated | Wolfe Research | Peer Perform |
| Jan-13-22 | Downgrade | Guggenheim | Buy → Neutral |
| Jan-12-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-10-21 | Resumed | Raymond James | Mkt Perform |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Neutral |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Sep-23-21 | Initiated | Needham | Buy |
| Jun-18-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jun-14-21 | Reiterated | Truist | Buy |
| Jun-11-21 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Jun-10-21 | Upgrade | UBS | Neutral → Buy |
| Jun-08-21 | Upgrade | Atlantic Equities | Underweight → Neutral |
| Jun-08-21 | Reiterated | Barclays | Equal Weight |
| Jun-08-21 | Upgrade | Citigroup | Sell → Neutral |
| Jun-08-21 | Reiterated | H.C. Wainwright | Buy |
| Jun-08-21 | Reiterated | Jefferies | Buy |
| Jun-08-21 | Reiterated | Morgan Stanley | Overweight |
| Jun-08-21 | Reiterated | RBC Capital Mkts | Sector Perform |
| Jun-08-21 | Upgrade | Robert W. Baird | Underperform → Neutral |
| Jun-08-21 | Reiterated | Stifel | Buy |
| Jun-08-21 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jun-07-21 | Upgrade | BofA Securities | Underperform → Neutral |
| Jun-07-21 | Upgrade | Cowen | Market Perform → Outperform |
| Jun-07-21 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Feb-05-21 | Downgrade | DZ Bank | Buy → Hold |
| Jan-29-21 | Upgrade | Stifel | Hold → Buy |
| Nov-10-20 | Upgrade | DZ Bank | Hold → Buy |
| Nov-09-20 | Downgrade | Atlantic Equities | Neutral → Underweight |
| Nov-09-20 | Downgrade | BofA Securities | Neutral → Underperform |
| Nov-09-20 | Downgrade | Cowen | Outperform → Market Perform |
| Nov-09-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-04-20 | Upgrade | BofA Securities | Underperform → Neutral |
| Nov-04-20 | Upgrade | Jefferies | Hold → Buy |
| Nov-04-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Oct-28-20 | Initiated | UBS | Neutral |
| Jul-27-20 | Upgrade | Morgan Stanley | Underweight → Overweight |
| Jun-22-20 | Downgrade | Barclays | Overweight → Equal Weight |
| Jun-22-20 | Reiterated | RBC Capital Mkts | Sector Perform |
| Jun-09-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Apr-23-20 | Downgrade | Citigroup | Neutral → Sell |
| Apr-23-20 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Jan-27-20 | Upgrade | Canaccord Genuity | Hold → Buy |
| Dec-13-19 | Upgrade | Credit Suisse | Underperform → Neutral |
| Dec-02-19 | Downgrade | Robert W. Baird | Neutral → Underperform |
View All
Biogen Inc Stock (BIIB) Latest News
Is Biogen (BIIB) Pricing Reflect Its Cash Flow Value After Mixed Long Term Returns - simplywall.st
Analysts Estimate Biogen Inc. (BIIB) to Report a Decline in Earnings: What to Look Out for - Finviz
Oppenheimer Adjusts Biogen Price Target to $225 From $205, Maintains Outperform Rating - marketscreener.com
Oppenheimer Raises Price Target for Biogen (BIIB) to $225 | BIIB Stock News - GuruFocus
Biogen Must Face Union Class Action Over Multiple Sclerosis Drug - Bloomberg Law News
Biogen's Autoimmune Disease Candidate Gets FDA's Breakthrough Status - Finviz
Biogen Can't Escape Amended Antitrust Suit Over MS Drug - Law360
FDA ‘Breakthrough’ status for Biogen’s litifilimab - The Pharma Letter
FDA grants breakthrough therapy designation to Biogen’s litifilimab - Investing.com
Biogen (BIIB) Achieves Breakthrough Therapy Status for CLE Treat - GuruFocus
Biogen’s Litifilimab Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus Erythematosus, a Disease With No Targeted Treatment Options - Biogen
FDA fast-tracks Biogen lupus drug for scarring skin disease with no targeted treatment - Stock Titan
US Market Recap: Can Biogen Inc. lead its sector in growthIndex Update & Weekly Setup with ROI Potential - mfd.ru
Incredible Growth of Recombinant Dna Technology Market - openPR.com
Expert Outlook: Biogen Through The Eyes Of 11 Analysts - Benzinga
Citigroup Maintains Neutral Rating on Biogen (BIIB), Raises Pric - GuruFocus
Tau Inhibitor Market Is Going to Boom |• Eli Lilly and Company • Biogen Inc. - openPR.com
Eisai Submits Marketing Authorisation Variation to EMA for Intraous Maintenance Dosing Every Four Weeks with Leqembi - marketscreener.com
Will FDA’s Priority Review of At‑Home LEQEMBI IQLIK Dosing Change Biogen’s (BIIB) Narrative - Yahoo Finance
Biogen Surpasses Expectations with Robust Quarterly Performance and Regulatory Milestone - AD HOC NEWS
Biogen (BIIB) Valuation Check As Shares Trade Below Analyst Targets And Long Term Returns Stay Under Pressure - Yahoo Finance
AEGON ASSET MANAGEMENT UK Plc Takes Position in Biogen Inc. $BIIB - MarketBeat
Biogen Inc. (BIIB) Stock Analysis: A Closer Look At Its 11.98% Potential Upside - DirectorsTalk Interviews
FDA Reviews Biogen's (BIIB) Alzheimer's Drug Lecanemab-irmb Appl - GuruFocus
FDA Accepts LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review - ACN Newswire
FDA Accepts LEQEMBI IQLIK (Lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Priority Review - 富途牛牛
Eisai and Biogen Launch LEQEMBI IQLIK, FDA Review Set for May 2026 - Intellectia AI
Eisai and Biogen Announce FDA Review of LEQEMBI IQLIK, a First-of-Its-Kind At-Home Injection Treatment for Alzheimer's Disease - Quiver Quantitative
FDA Accepts LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer’s Disease under Priority Review - Biogen
FDA Accepts LEQEMBI® IQLIKTM (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review - StreetInsider
FDA grants priority review to weekly at-home Alzheimer's injections - Stock Titan
Sector Gamma AS Has $10.57 Million Holdings in Biogen Inc. $BIIB - MarketBeat
AMF Tjanstepension AB Sells 25,636 Shares of Biogen Inc. $BIIB - MarketBeat
Assessing Biogen (BIIB) Valuation After New EU Approval For High Dose Spinraza - simplywall.st
Looking Into Biogen Inc's Recent Short Interest - Sahm
Biogen (NASDAQ:BIIB) Stock Price Expected to Rise, Wedbush Analyst Says - MarketBeat
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Teleflex (TFX) and Biogen (BIIB) - The Globe and Mail
High Dose SPINRAZA EU Approval Might Change The Case For Investing In Biogen (BIIB) - simplywall.st
Postpartum Depression Drugs Market Size to Surpass USD 1.97 Billion by 2033, Due to Increasing Awareness & Fast Development of Pharmaceuticals – SNS Insider - GlobeNewswire Inc.
Priya Singhal’s Blueprint For Biogen’s Next Act - Citeline News & Insights
Spinocerebellar Ataxias Pipeline 2025: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Biogen Inc, BioXcel Corp, Celavie Biosciences, Ionis Pharma - Barchart.com
Biogen Inc (BIIB) Shares Up 3.16% on Jan 21 - GuruFocus
Gene Therapy Market Innovations and Key Players: Biogen, - openPR.com
Rakuten Investment Management Inc. Buys Shares of 198,572 Biogen Inc. $BIIB - MarketBeat
Patient Capital Management LLC Has $55.56 Million Stake in Biogen Inc. $BIIB - MarketBeat
Biogen’s High Dose Spinraza Win Extends SMA Treatment Options In EU - simplywall.st
Massachusetts Financial Services Co. MA Purchases 11,685 Shares of Biogen Inc. $BIIB - MarketBeat
Biogen’s Alisha Alaimo On The Company’s Next Big Commercial Build - Citeline News & Insights
3 Biotech Stocks That Look Like “Sure-Fire” Winners in 2026 - Yahoo Finance
40 Under 40: Kevin Conway, Biogen - Medical Marketing and Media
(BIIB) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Biogen Inc Stock (BIIB) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
0.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):